Meredith L McMorrow
Overview
Explore the profile of Meredith L McMorrow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
1716
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dawood F, McMorrow M
Lancet Respir Med
. 2025 Jan;
13(2):106-108.
PMID: 39799950
No abstract available.
2.
Roper L, Link-Gelles R, Surie D, DeCuir J, Zambrano L, Prill M, et al.
Vaccine
. 2025 Jan;
45():126633.
PMID: 39755055
During 2023, the Centers for Disease Control and Prevention (CDC) recommended the first respiratory syncytial virus (RSV) immunizations intended for widespread use in the United States to prevent severe RSV...
3.
Moline H, Toepfer A, Tannis A, Weinberg G, Staat M, Halasa N, et al.
JAMA Pediatr
. 2024 Dec;
179(2):179-187.
PMID: 39652359
Importance: During the 2023-2024 respiratory syncytial virus (RSV) season in the United States, 2 new RSV prevention products were recommended to protect infants in their first RSV season: nirsevimab and...
4.
Hutton D, Prosser L, Rose A, Mercon K, Ortega-Sanchez I, Leidner A, et al.
Pediatrics
. 2024 Nov;
154(6).
PMID: 39582316
Background And Objectives: Respiratory syncytial virus (RSV) causes substantial hospitalization in US infants. The Advisory Committee on Immunization Practices recommended nirsevimab in infants younger than 8 months born during or...
5.
Hutton D, Prosser L, Rose A, Mercon K, Ortega-Sanchez I, Leidner A, et al.
Pediatrics
. 2024 Nov;
154(6).
PMID: 39582303
Background And Objectives: Respiratory syncytial virus (RSV) commonly causes hospitalization among US infants. A maternal vaccine preventing RSV in infants, RSV bivalent prefusion F maternal vaccine (RSVpreF), was approved by...
6.
Sun K, Bhiman J, Tempia S, Kleynhans J, Madzorera V, Mkhize Q, et al.
Nat Med
. 2024 Jul;
30(10):2805-2812.
PMID: 39060660
Serum neutralizing antibodies (nAbs) induced by vaccination have been linked to protection against symptomatic and severe coronavirus disease 2019. However, much less is known about the efficacy of nAbs in...
7.
McMorrow M, Moline H, Toepfer A, Halasa N, Schuster J, Staat M, et al.
Pediatrics
. 2024 Jun;
154(1).
PMID: 38841769
Background: The coronavirus disease 2019 pandemic disrupted respiratory syncytial virus (RSV) seasonality resulting in early, atypical RSV seasons in 2021 and 2022, with an intense 2022 peak overwhelming many pediatric...
8.
Dawood F, Payne A, McMorrow M
JAMA
. 2024 Apr;
331(21):1799-1800.
PMID: 38602685
No abstract available.
9.
Surie D, Yuengling K, DeCuir J, Zhu Y, Lauring A, Gaglani M, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e244954.
PMID: 38573635
Importance: On June 21, 2023, the Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccines for adults aged 60 years and older using shared clinical...
10.
Clopper B, Zhou Y, Tannis A, Staat M, Rice M, Boom J, et al.
J Pediatr
. 2024 Apr;
271:114045.
PMID: 38561048
Objective: To assess medical costs of hospitalizations and emergency department (ED) care associated with respiratory syncytial virus (RSV) disease in children enrolled in the New Vaccine Surveillance Network. Study Design:...